This study aims at comparing the efficacy and safety of recombinant human activated protein C to that of low dose of corticosteroids and at investigating the interaction between these drugs in the management of septic shock
Septic shock still places a burden in the healthcare system round around the world. In the early 20ties, clinical trials suggested potential benefits from activated protein C in severe sepsis and of corticosteroids when given to adults with refractory shock. More recent studies suggested that patients with moderate sepsis or septic shock may not benefit from either activated protein C or corticosteroids. Therefore, current international guidelines suggest that physicians may consider using these drugs in the more severe cases of sepsis. The main risk associated with the use of activated protein C is bleeding and the main risk associated with the use of steroids is superinfection. It is paramount that a new adequately powered trial explores the benefit/risk ratio of these two drugs and of their combination in a population of adult patients with septic shock. After the withdrawal of Xigris in October 2011, the study was suspended and restarted in June 2012 to investigate the benefit to risk ratio of corticosteroids.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
1,241
placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of fludrocortisone given through the nasogastric tube once a day for seven days plus placebo of activated protein C given as a continuous infusion for 96 hours
hydrocortisone will be given as 50mg iv bolus every 6 hours for seven days and a tablet of 50µg of fludrocortisone will be given once a day via the nasogastric tube for seven days and a placebo of activated protein C will be given as a continuous infusion for 96 hours
activated protein C will be given as a continuous infusion at a dose of 24 µg/kg/h four 96 hours and hydrocortisone placebo as an iv bolus every 6 hours and fludrocortisone placebo once a day through the gastric tube will be given for seven days
Henri Mondor Hospital
Créteil, France
Raymond Poincaré Hospital
Garches, France
Pitié Salpêtrière Hospital
Paris, France
Saint Josef Hospital
Paris, France
90-day mortality
Time frame: 90 day
mortality at 28 day
Time frame: 28-day
mortality at ICU discharge
Time frame: ICU discharge
mortality at hospital discharge
Time frame: hospital discharge
mortality at 6 months
Time frame: 6 months
decision to withhold or withdraw active treatments
Time frame: up to 90 days
Time to wean vasopressor therapy
Time frame: up to 90 days
number of days alive and free of vasopressor therapy
Time frame: up to 90 days
time to achieve an SOFA score of less than 6
Time frame: up to 90 days
number of days alive with a SOFA score < 6 points
Time frame: up to 90 days
time to wean mechanical ventilation
Time frame: up to 90 days
number of days alive and free of mechanical ventilation
Time frame: up to 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
96 hours continuous infusion of 24µg/kg/h of activated protein C plus seven day treatment with 50mg iv bolus of hydrocortisone every 6 hours and 50µg of fludrocortisone via the nasogastric tube once a day
Length of intensive care unit and hospital stay
Time frame: up to hospital discharge
acquisition of new infection
Time frame: up to 180 days
new episode of sepsis
Time frame: up to 90 days
new episode of septic shock
Time frame: up to 90 days
bleeding events
Time frame: up to 90 days
neurological sequels at intensive care unit and at hospital discharge and at 90 and 180 days
Time frame: up to 6 months